| |
Learn de-risking strategies in our whitepaper and explore the future of precision treatments from our survey of 100+ oncology professionals.
|
|
Today’s Big NewsOct 14, 2024 |
|
Gene and cellular therapies hold the extraordinary potential to transform
global health care. Download the QPS White Paper to explore the 5 critical
criteria to consider when choosing the best CRO for your next cell and gene
therapy development program.
|
|
| By Angus Liu As payers tally up the potential costs of anti-amyloid antibodies for Alzheimer’s disease, a new study suggests that the vial design for Eisai and Biogen’s Leqembi could result in hundreds of millions of dollars in wasted spending each year for Medicare. |
|
|
|
By James Waldron After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is scooping up the biotech for $2.5 billion. |
By Kevin Dunleavy The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company. On Monday, Vanda revealed that it has turned down a second $8-per-share takeover offer from Cycle, which works out to a $488-million deal to buy out the 18-year-old pharma. |
By Nick Paul Taylor Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis but will continue to advance the candidate in another indication. |
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now.
|
|
By Ben Adams Big Pharmas, medical device companies and healthcare groups have teamed up with the International Society on Thrombosis and Haemostasis (ISTH) for a new campaign aimed at boosting awareness about how to spot and treat blood clots. |
By Conor Hale CMR Surgical obtained a de novo clearance from the FDA for its Versius surgical system, allowing its modular laparoscopic robot to enter U.S. shores. |
By Zoey Becker Eli Lilly's drug outperformed Johnson & Johnson's established Stelara in a phase 3 study that looked at histologic disease responses over 52 weeks. |
By James Waldron GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. |
By Andrea Park A year after kicking off a star-studded campaign to highlight the stories of real patients with atopic dermatitis, Incyte has expanded it to represent even more patients—including a very recognizable face in the world of skin health. |
By Zoey Becker While a Trump win could be slightly more positive for the industry, neither candidate is expected to make significant waves in the sector due to a divided congress and the already-passed Inflation Reduction Act. |
By Nick Paul Taylor Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to improve progression-free survival, the biotech is continuing to analyze aspects of the data including a “positive efficacy trend” in a prespecified subgroup before deciding on its next steps. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals. |
|
|---|
|
|
|
Thursday, October 24, 2024 | 1pm ET / 10am PT We will explore how incorporating comprehensive genetic services, like genetic testing access programs and clinical trial matching services, can increase identification of patients who meet program-specific inclusion/exclusion criteria, helping more patients benefit from life-changing therapeutics. Register today!
|
|
| eBookNeed the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
